Background. Prostate specific antigen (PSA) is useful as a tumor marker for monitoring patients with prostate cancer after definitive therapy. Limitations have been noted when PSA was used for the early detection of prostate cancer. The use of prostate specific antigen density [PSAD = PSA (ng/ml)/pr
Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
β Scribed by G. Raviv; A. R. Zlotta; Th. Janssen; F. Descamps; J. P. Vanegas; A. Verhest; C. C. Schulman
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 555 KB
- Volume
- 77
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The volume of the transition zone was also measured by TRUS in 134 patients.
## BACKGROUND. To improve the clinical usefulness of prostate specific antigen (PSA),
## Abstract ## BACKGROUND In the current study, the authors set out to investigate the possibility that increased prostateβspecific antigen (PSA) levels in Dutch and Japanese men without suspicious findings at initial prostate cancer screening were indicative of the risk of newly developing clinic
## BACKGROUND. Human glandular kallikrein (hK2), the prostate specific antigen (PSA) close homologue, possesses approximately 80% structure identity with PSA. The identification of PSA was an important step in the detection of prostate carcinoma (PCa). Thus, hK2 measurement in the serum has the po
## Abstract ## BACKGROUND The objective of this study was to evaluate the prostate specific antigen (PSA) density (PSAD) (the quotient of PSA and prostate volume) compared with the percent free PSA (%fPSA) in different total PSA (tPSA) ranges from 2 ng/mL to 20 ng/mL. Possible cutβoff levels depen